Iradimed (IRMD) AI Stock Analysis

• Market Cap: $841.36M
• Dividend Yield: 0.97%
• Average Volume (3M): 54.73K
• Price to Earnings (P/E): 41.0
• Beta (1Y): 0.73
• Revenue Growth: 11.73%
• EPS Growth: 10.27%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 0.49
• Shares Outstanding: 12,715,109
• 10 Day Avg. Volume: 43,763
• 30 Day Avg. Volume: 54,731
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 9.51
• Enterprise Value/Gross Profit: 12.36
• Enterprise Value/Ebitda: 30.30
• 1Y Price Target: $71.00
• Price Target Upside: 7.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 78 Outperform
• Price Target: $75.00 ▲(13.34%Upside)

Iradimed's overall stock score is strong, driven by excellent financial performance and positive earnings call sentiment. Technical analysis and valuation indicate some caution with overbought signals and high P/E ratio, while corporate events reflect solid governance support. The company's growth prospects appear robust, yet monitoring for potential challenges in international sales and operational efficiencies is advised.

Iradimed Business Overview & Revenue Model

Company Description

Iradimed Corporation (IRMD) is a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices. The company specializes in developing and commercializing advanced MRI-compatible patient monitoring systems and non-magnetic infusion pumps. These products are designed to meet the unique needs of MRI environments, ensuring patient safety and compliance with strict regulatory standards. Iradimed's solutions are widely used in hospitals and medical facilities around the world, catering to a critical niche in the healthcare sector.

How the Company Makes Money

Iradimed makes money primarily through the sale of its MRI-compatible medical devices, including patient monitoring systems and infusion pumps. The company generates revenue by selling these products directly to hospitals, healthcare facilities, and medical institutions globally. Additionally, Iradimed may earn income from service contracts, maintenance agreements, and spare parts related to their equipment. The company's revenue streams are supported by its strong reputation for quality and compliance, and it may also engage in strategic partnerships or collaborations that enhance its market reach and product offerings.

Iradimed Financial Statement Overview

Summary

Iradimed demonstrates strong financial performance with robust revenue growth, high gross profit margins, and a solid balance sheet characterized by low debt. Cash flow generation is stable, though capital expenditures slightly impact free cash flow growth. Overall, the company is financially healthy but could improve net profit margins.

Income Statement

Iradimed has demonstrated robust revenue growth with a 41.0% increase from 2022 to 2023 and a further 14.0% increase in 2024. Gross profit margins have remained strong, averaging around 77% over recent periods. The company maintains healthy EBIT and EBITDA margins, showcasing strong operational efficiency and profitability. However, the net profit margin, while solid, indicates room for further optimization.

Balance Sheet

The balance sheet of Iradimed is very healthy, with a remarkably low debt-to-equity ratio, indicating minimal leverage risk. The equity ratio is strong, reflecting a robust balance of equity to total assets. ROE is impressive, showing efficient use of equity to generate profits. Overall, the company has a solid financial position with low liabilities relative to equity.

Cash Flow

Iradimed shows a positive cash flow trend, with stable free cash flow generation despite fluctuations in capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion from profits. The free cash flow to net income ratio is consistent, though recent capital expenditures have slightly impacted free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	75.15M	73.24M	65.56M	53.30M	41.81M	31.72M
Gross Profit	57.80M	56.35M	50.16M	41.28M	32.05M	23.57M
EBITDA	23.58M	22.78M	20.80M	16.30M	11.22M	582.73K
Net Income	19.78M	19.23M	17.19M	12.83M	9.33M	1.37M
Balance Sheet
Total Assets	101.73M	98.33M	92.16M	85.51M	82.88M	71.07M
Cash, Cash Equivalents and Short-Term Investments	50.33M	52.23M	49.76M	57.96M	62.50M	51.98M
Total Debt	59.22K	154.69K	2.04M	2.21M	2.48M	2.72M
Total Liabilities	11.68M	11.51M	20.74M	11.84M	10.71M	9.68M
Stockholders Equity	90.05M	86.82M	71.42M	73.67M	72.17M	61.38M
Cash Flow
Free Cash Flow	14.00M	17.62M	5.46M	8.17M	10.52M	5.18M
Operating Cash Flow	26.03M	25.62M	13.47M	10.04M	11.26M	5.82M
Investing Cash Flow	-12.26M	-8.82M	-8.01M	-1.37M	648.24K	246.97K
Financing Cash Flow	-8.57M	-14.34M	-13.66M	-12.71M	24.43K	522.48K

Iradimed Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 66.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Positive. The current price of 66.17 is above the 20-day moving average (MA) of 58.17, above the 50-day MA of 58.33, and above the 200-day MA of 54.98, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 76.87 is Negative, neither overbought nor oversold. The STOCH value of 89.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRMD.

Iradimed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	78 Outperform	$841.36M	41.04	23.75%	0.97%	11.73%	10.27%
Sector *	65 Neutral	¥351.75B	9.37	-3.16%	2.47%	11.67%	-10.80%
SIBN	61 Neutral	$741.07M	―	-15.96%	―	22.60%	41.26%
BVS	51 Neutral	$507.65M	―	-19.79%	―	8.60%	-42.76%
CBLL	48 Neutral	$511.06M	―	26.25%	―	―	―
AVNS	47 Neutral	$507.76M	45.80	-36.78%	―	1.34%	-530.36%
RXST	45 Neutral	$316.97M	―	-11.98%	―	46.69%	46.68%

Iradimed Corporate Events

Iradimed Holds Annual Stockholders Meeting, Key Decisions Made

On June 19, 2025, Iradimed Corporation held its Annual Meeting of Stockholders, where several key decisions were made. Stockholders elected five directors to the Board, ratified RSM US LLP as the independent auditor for 2025, and approved an advisory resolution on executive compensation. These outcomes reflect shareholder support for the company’s leadership and strategic direction, potentially impacting its governance and operational oversight.

The most recent analyst rating on (IRMD) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.